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1. Introduction 
 
Longitudinal magnetic resonance imaging (MRI) studies have shown that the brain 
might experience progressive tissue loss after the first psychotic onset of 
schizophrenia (Ho et al., 2003; Kasai et al., 2003; Lieberman et al., 2005; 
Nakamura et al., 2007). 
The prefrontal cortex is among the major structures that have received the most 
attention in the search for the neural substrate of schizophrenia (Suzuki et al., 
2005); the human prefrontal cortex is, though, a large and highly differentiated 
brain region. It is conceivable to argue that specific subregions within the frontal 
cortex might be distinctively involved in the pathophysiology of schizophrenia 
(Crespo-Facorro et al., 2000). Within the prefrontal cortex, imaging studies have 
shown a distinction between the straight gyrus (SG) and the orbitofrontal cortex 
during several cognitive tasks, suggesting that the SG may be part of a circuit that 
mediates some specific emotional functions in humans (Andreasen et al., 1995). 
Although the orbitofrontal cortex has been extensively studied in schizophrenia, 
less attention has been paid to the SG. The SG is situated medially to the olfactory 
groove (olfactory sulcus) at the ventromedial edge of the frontal lobe, and is 
considered to be the frontal extension of the anterior cingulate gyrus. Animal 
studies have reported that the SG is a part of the anterior limbic system and is 
specifically connected to auditory cortex neurons in the convexity of the superior 
temporal gyrus (Müeller-Preuss et al., 1980). In line with other studies (Szendi et 
al., 2006; Takayanagi et al., 2010), we have reported that SG morphometry did not 
significantly differ between healthy subjects and schizophrenia spectrum patients 
at the onset of psychosis (Roiz-Santiañez et al., 2011). However, studies in chronic 
schizophrenia patients have revealed SG anomalies (Chemerinski et al., 2002; 
Suzuki et al., 2005). To the best of our knowledge, no longitudinal studies have 
investigated the possibility of progressive SG volume loss in first-episode 
schizophrenia patients using a region-of-interest (ROI) methodology. 
The primary aim of this study was, using a highly reliable ROI technique, to 
examine the progressive gray matter volume change of the SG in first-episode 
schizophrenia-spectrum patients compared with healthy subjects. The second 
purpose was to study the relationship between SG volume change and clinical 
symptoms. We hypothesized that first-episode schizophrenia-spectrum patients 
would show a larger gray matter volume decrease over time in the SG 
compared to healthy subjects. 
 
 
 
 
 
 
 
2. Method 
 
2.1. Subjects 
Ninety-three first-episode schizophrenia spectrum patients (59 males and 34 
females) and seventy healthy subjects (44 males and 26 females) were included in 
this study. Patients were drawn from a large prospective longitudinal study on first-
episode psychosis (PAFIP) conducted at the University Hospital Marques de 
Valdecilla, Santander, Spain. A detailed description of our program has been 
previously reported (Pelayo-Teran et al., 2008). All the participants were included 
in our previous cross-sectional SG study (Roiz-Santiañez et al., 2011). Patients 
and healthy subjects were included in this study only when two MRI scans with an 
interval of about 1 year (mean=384.60 days, S.D.=33.87) were available. At 6 
months after enrollment in the study, their Axis I diagnoses were as follows: 
schizophrenia (N=53; 57.0%), schizophreniform disorder (N=27; 29.0%), 
schizoaffective disorder (N=2; 2.2%), brief reactive psychosis (N=6; 6.5%), not 
otherwise specified psychosis (N=4; 4.3%) and delusional disorder (N=1, 1.1%). 
Mean age at onset was 28.29 years (S.D.=7.83). The mean duration of psychosis 
at intake was 11.64months (S.D.=18.08). At baseline, 17 patients were taking a 
typical antipsychotic (haloperidol) and 76 patientswere on atypical antipsychotics 
(17 olanzapine, 16 risperidone, 14 quetiapine, 17 ziprasidone and 12 aripiprazol). 
At the 1-year assessment all but two patients were on antipsychotics (haloperidol: 
11, olanzapine: 19, risperidone: 18, quetiapine: 16, ziprasidone: 12, risperdal 
consta: 4, aripiprazole: 11). The mean dose in chlorpromazine equivalents 
(Andreasen et al., 2010) was 224.86 mg/day. 
 
2.2. Clinical assessments 
Clinical symptoms were rated using the Brief Psychiatric Rating Scale total (BPRS) 
(Overall and Gorman, 1962), the Scale for the Assessment of Negative Symptoms 
(SANS) (Andreasen, 1983) and the Scale for the Assessment of Positive 
Symptoms (SAPS) (Andreasen, 1984). The mean values at baseline were 61.90 
(12.38) for the BPRS, 6.28 (5.15) for the SANS and 13.57 (4.36) for the SAPS. At 
follow up the mean values were 30.58 (8.19) for the BPRS, 4.19 (5.15) for the 
SANS and 1.31 (2.67) for the SAPS. 
 
2.3. MRI acquisition and Image processing 
Subjects were scanned twice on a 1.5 Tesla General Electric SIGNA System (GE 
Medical Systems, Milwaukee, WI) at the University Hospital of Cantabria. Three-
dimensional T1-weighted images and two-dimensional proton density (PD) and T2 
sequenceswere acquired. Imaging parameters have been previously described 
(Crespo-Facorroet al., 2007). 
Images were processed using the software BRAINS2 (Andreasen et al., 1996; 
Magnotta et al., 2002). In short, T1-weighted images were spatially normalized and 
resampled to 1.0-mm3 voxels. T2-and PD-weighted images were aligned to the 
spatially normalized T1-weighted image. In order to classify volumes into gray 
matter (GM), white matter (WM), and cerebrospinal fluid (CSF), the data sets were 
segmented by using the multispectral data and a discriminant analysis method 
based on automated training class selection (Harris et al., 1999).  
The tissue-classified image was then used to generate a triangle-based iso-surface 
with a threshold of 130 representing pure gray matter, which corresponds to the 
parametric center of the cortex and serves as a useful estimate of its physical 
center (Magnotta et al., 1999). Hand-traced regions of interest (ROIs) were used to 
surround contiguous areas of the gray-matter triangle isosurface. On each two-
dimensional (2D) slice, the cortical surface is visualized as a continuous contour 
that represents the intersection between the 2D plane and the three-dimensional 
(3D) triangulated surface. 
The SG was manually traced on consecutive transaxial slices as described in Roiz-
Santiañez et al. (2011). Briefly, tracing begins on the most inferior slice which 
contains the SG and moves upward to the most superior slice in which the 
olfactory sulcus (OS) can be identified. In each transaxial slice, the SG is defined 
as the portion of the frontal lobe medial to the OS. When the OS is interrupted by 
another frontal region, an orthogonal line is traced from the anterior extremity of the 
OS to the medial surface of the hemisphere. A single rater (V O-GF) traced all the 
ROIs. The rater was blinded to the time (baseline or 1 year) and diagnosis. The 
reliability study for this method was performed on a set of 10 MRI scans using the 
original tracing from (Crespo-Facorro et al., 1999) as gold standard. Both the intra-
class and inter-class R coefficients for SG gray matter volume measurements 
were greater than 0.95. 
 
2.4. Statistical analysis 
All statistical analyses were performed with the Statistical Program for the Social 
Sciences (SPSS v 19.0, SPSS Inc., Chicago, 2006). To test the hypothesis that 
patients and healthy subjects would present different progressive SG volume 
changes, we performed repeated measures analysis of covariance (repeated 
measures ANCOVA) for the left and right SG gray matter volume separately. The 
betweensubject factor was the group (patient vs. healthy subject) and the within-
subject factor was time (baseline and 1 year). Age and intracranial volume were 
included as covariates. We have also performed similar analysis of only 
schizophrenia patients vs. healthy controls. Pearson's productmoment correlation 
coefficients with age and intracranial volume as covariates were calculated to 
examine the relationships between percent SG gray matter volume change 
(100×(Vol2−Vol1)/Vol1) and medication dose and clinical variables (total scores of 
SANS, SAPS and BPRS) both at baseline and 1-year follow-up. Throughout, a 
two-tailed alpha-level of 0.05 was used for statistical testing. 
 
3. Results 
There were no significant differences between groups with regard to age, gender, 
laterality, intracranial volume, parental socioeconomic status, alcohol or cannabis 
use (all P>0.115). Inter-scan interval did not differ significantly (F(1,61)=0.04; 
P=0.841) between patients (mean=385.06 days, S.D.=36.98 ) and healthy subjects 
(mean= 383.98 days, S.D.=29.48). These data are available upon request. 
The SG gray matter volumes at baseline and follow-up and the percentage of 
volume change are described in.  
 
There were no significant effects of time (F(1,159)b0.94; P>0.33) or diagnosis 
group (F(1,159)b2.76; P>0.10) (patients vs. healthy subjects). Neither were there 
significant significant group-by-time interactions for any of the ROIs analysed 
(F(1,159)b0.12; P>0.72). No significant 
differences were found either when males and females were analyzed separately. 
Similarly, the analysis of only right-handed individuals (87 patients and 65 healthy 
subjects) did not show significant differences. 
Analyses conducted with patients on either atypical or typical (haloperidol) 
antipsychotics as the independent variable did not reveal statistically significant 
results. It is also of interest that there were no significant differences when 
diagnosis (schizophrenia, schizophreniform disorder and nonschizophrenic non-
affective (NSNA) psychoses patients) was included as the between-subject factor. 
No significant differences were found between control subjects and schizophrenia 
patients, (all P's>0.196). Interestingly, there were no significant differences when 
patients with positive symptoms predominance vs. negative symptoms were 
included as the betweensubject factor (all P's>0.14). 
There were no significant correlations between clinical variables (SANS, SAPS and 
BPRS total scores) at either baseline or 1 year follow-up assessment and the 
percent change of SG gray matter volumes (all P's>0.204). Neither were there 
significant correlations between clinical improvement and ROI changes over time 
(all P's>0.44) Correlations between SG gray matter volume change and medication 
dose were very weak (all rb0.23). 
 
4. Discussion 
In a large representative sample of schizophrenia-spectrum patients in a first 
episode of psychosis, we found that during a 1-year period: 1. Patients did not 
show a different pattern of SG gray matter volume change compared to healthy 
subjects; 2. SG gray matter volume change was not associated with clinical 
variables.  
To the best of our knowledge, this is the first longitudinal MRI study in first-episode 
schizophrenia-spectrum patients that investigate the SG morphology using an ROI 
technique. A similar pattern of SG volume loss between patients and healthy 
subjects was observed. Moreover, there was no significant effect of time 
(F(1,159)b0.94; P>0.33). A high volume loss was found in both groups. This might 
be explained by the fact that the SG is a relatively small structure and the variance 
of its volume was very high. The SG volume loss found was uncommonly high. The 
prefrontal cortex has been described as one of the structures with most substantial 
progressive volume change (Raz et al., 1997) and sub-regions within the prefrontal 
cortex might show different rates of volume change (DeLisi et al., 1997; Gur et al., 
1998). Although contrary to our hypothesis, the results are in accordance with 
some longitudinal studies that observed similar patterns of brain volume change 
between patients and healthy subjects (Puri et al., 2001; James et al., 2002; 
Dickey et al., 2004; James et al., 2004).  
 
 
Our negative results herein seem to provide further support to the hypothesis that 
biological mechanisms implicated in the pathophysiology of schizophrenia seem to 
affect more global structural 
characteristics such as total brain or lateral ventricular volume (Crespo-Facorro et 
al., 2009) rather than affecting particular cortical regions in the short term (i.e., 
straight gyrus, temporal pole). 
It has been suggested that atypical antipsychotic medication might attenuate the 
progressive brain changes in schizophrenia (Cahn et al., 2002). However, when we 
compared the SG volume change between patients who were most of the time on 
atypical antipsychotic medication with those on typical antipsychotic medication, 
we did not observe any significant difference. Additionally, we did not identify 
significant correlations between SG volume change and length of time taking 
antipsychotic medication. It is also of note that, in a previous study (Crespo-
Facorro et al., 2008), we did not find significant differences in cortical 
morphological changes after 1 year of treatment in patients with non-affective 
psychosis treated with either atypical or low doses of typical antipsychotics. 
In this study, the SG volume change was not correlated with clinical variables. Our 
previous SG cross-sectional study (Roiz-Santiañez et al., 2011) also revealed that 
SG gray matter volume was not correlated with clinical variables by the onset of 
psychosis. Some longitudinal studies (Gur et al., 1998; Takahashi et al., 2009; 
Takahashi et al., 2011) have reported gray matter progressive changes associated 
with clinical symptoms when longer periods of time were investigated. Lengthier 
studies are warranted to investigate the association between the SG volume 
change and the severity of symptomatology. 
The sample size and a careful control of possible confounding factors (age, sex, 
handedness and other demographic factors) add strength to the conclusions drawn 
from this study. However, there were some limitations. First, the diagnostic 
heterogeneity of the sample might bias our findings. For this reason we have 
repeated all the statistical analyses leaving out the two patients with schizoaffective 
disorder and the results were once again similar. Second, we did not investigate 
morphometric change of other cortical brain regions functionally and structurally 
related to the SG (i.e., medial, anterior, posterior and lateral orbital gyri). Finally, as 
indicated previously, another limitation is the relatively short follow-up period. If the 
patient's illness progresses over a longer time period, we are only studying a very 
limited period of the illness. 
In summary, we have observed a similar pattern of SG gray matter volume change 
over a 1-year period between first-episode schizophrenia-spectrum patients and 
healthy subjects. In addition, volume change of the SG does not seem to 
significantly influence the severity of symptomatology. 
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